We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
Read MoreHide Full Article
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $124.30, marking a -1.03% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 1.65%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 3.07%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 3.08% over the previous month, trailing the performance of the Medical sector with its gain of 3.59%, and the S&P 500's gain of 0.48%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company's upcoming EPS is projected at -$5.31, signifying a 364.18% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.36 billion, up 3.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.79 per share and revenue of $30.37 billion, which would represent changes of -109.69% and +3.16%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.73% fall in the Zacks Consensus EPS estimate. Gilead Sciences presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 147, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.
View the Zacks #1 Rank List
Image: Bigstock
Gilead Sciences (GILD) Stock Falls Amid Market Uptick: What Investors Need to Know
In the latest trading session, Gilead Sciences (GILD - Free Report) closed at $124.30, marking a -1.03% move from the previous day. The stock's performance was behind the S&P 500's daily gain of 1.65%. Meanwhile, the Dow gained 0.92%, and the Nasdaq, a tech-heavy index, added 3.07%.
Shares of the HIV and hepatitis C drugmaker witnessed a loss of 3.08% over the previous month, trailing the performance of the Medical sector with its gain of 3.59%, and the S&P 500's gain of 0.48%.
The investment community will be paying close attention to the earnings performance of Gilead Sciences in its upcoming release. The company's upcoming EPS is projected at -$5.31, signifying a 364.18% drop compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $7.36 billion, up 3.98% from the year-ago period.
For the full year, the Zacks Consensus Estimates are projecting earnings of -$0.79 per share and revenue of $30.37 billion, which would represent changes of -109.69% and +3.16%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. Such recent modifications usually signify the changing landscape of near-term business trends. Therefore, positive revisions in estimates convey analysts' confidence in the business performance and profit potential.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the past month, there's been a 1.73% fall in the Zacks Consensus EPS estimate. Gilead Sciences presently features a Zacks Rank of #3 (Hold).
The Medical - Biomedical and Genetics industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 147, finds itself in the bottom 40% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow GILD in the coming trading sessions, be sure to utilize Zacks.com.